Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy- and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer

Anticancer Research

Volumn 16, Issue 4 B, 1996, Pages 2289-2293

  Tähtelä, Riitta ^a,b   Thölix, Eric ^c  

^a Yhtyneet Laboratoriot Oy   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c VAASA CENTRAL HOSPITAL   (Finland)

Author keywords

Bone formation; Bone resorption; Breast cancer; Metastatic bone disease; Propeptides of type I procollagen; Type I collagen

Indexed keywords

COLLAGEN TYPE 1; PEPTIDE;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BONE METASTASIS; BONE REMODELING; BREAST CANCER; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGEN SYNTHESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HUMAN; OSSIFICATION; OSTEOLYSIS; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; BONE NEOPLASMS; BREAST NEOPLASMS; COLLAGEN; FEMALE; HUMANS; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0029813474     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Coleman R. Incidence and distribution of bone metastases: In: Metastatic bone disease. Fundamental and clinical aspects. (Diel IJ, Kaufmann M, G. Bastert G, eds). Springer-Verlag Berlin Heidelberg, 1994, pp 20-30.
2. Kamby C, Egsmose C, Söletormos G, Dombernovsky P: The diagnostic and prognostic value of serum bone Gla protein (osteocalcin) in patients with recurrent breast cancer. Scand J Clin Lab Invest 53: 439-446, 1993.
3. Francini G, Gonnelli S, Petrioli R, et al: Procollagen type I carboxyterminal propeptide as a marker of osteoblastic bone metastases. Cancer Epidem, Biomarkers & Prevention. 2: 125-129, 1993.
4. Lipton A, Demers L, Daniloff Y, et al: Increased urinary excretion of pyridinium cross-links in cancer patients. Clin Chem 39: 614-618, 1993.
5. Pecherstorfer M, Zimmer-Roth I, Schilling T, et al: The diagnostic value of urinary pyridinium crosslinks of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrin Metab 80: 97-103, 1995.
6. Withold W, Georgescu G, Khakzad H, et al: Efficacy of simultaneous determination of bone alkaline phosphatase mass concentration in serum and urinary excretion of pyridinium cross-links for detection of bone metastases. Clin Biochem 28: 511-517, 1995.
7. Risteli L, Risteli J: Biochemical markers of bone metabolism. Ann Med 25: 385-393, 1993.
8. Melkko J, Hellevik T, Risteli L, Risteli J, Smedsrod B: Clearance of the amino-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med 179: 405-412, 1994.
9. Smedsrod B, Melkko J, Risteli L, Risteli J: Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 271: 345-350, 1990.
10. Melkko J, Niemi S, Risteli L, Risteli J: Radioimmunoassay of the carboxy-terminal propeptide of human type I procollagen. Clin Chem 36: 1328-1332, 1993.
11. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L: Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of hone collagen degradation. Clin Chem 39: 635-640, 1993.
12. Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J: Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res 8: 127-132, 1993.
13. Charles P, Mosekilde L, Risteli L, Risteli J, Eriksen EF: Assesment of bone remodelling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner 24: 81-94, 1994.
14. Tähtelä R, Turpeinen M, Sorva R, Karonen SL: The aminoterminal propeptide of type I procollagen; evaluation of a commercial kit and values in healthy subjects. Submitted for publication.
15. Kylmälä T, Tammela TLJ, Risteli L, Risteli J, Kontturi M, Elomaa I: Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 71: 1061-1064, 1995.
16. Kylmälä T, Tammela T, Risteli L, Risteli J, Taube T, Elomaa I: Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish prostate cancer group. Eur J Cancer 29A: 821-825, 1993.
17. Piovesan A, Berruti A, Osella G, Raucci CA, Torta M, Dogliotti L, Angeli A: Serum levels of carboxyterminal propeptide of type I procollagen in cancer patients with osteoblastic and osteolytic bone metastases. Int J Biol Markers 9: 243-246, 1994.
18. Clohisy DR, Bar-Shavit Z, Chappel JC, Teitelbaum SL. Dihydroxyvitamin D3 modulates bone marrow precursor proliferation and differentiation: upregulation of mannose receptor. J Biol Chem 262: 15922-15929, 1987.
19. Shepherd VL, Konish MG, Stahl P: Dexamethasone increases expression of mannose receptors and decreases extracellular lysosomal enzyme accumulation in macrophages. J Biol Chem 260: 160-164, 1985.
20. Schreiber S, Blum JS, Chappel JC, Stenson W, Stahl PD, Teitelbaum SL, Perkins SL: Prostaglandin E specifically upregulates the expression of the mannose-receptor on mouse bone marrow-derived macrophages. Cell Regul I: 403-413, 1990.